Alle Storys
Folgen
Keine Story von Zeltia Group mehr verpassen.

Zeltia Group

Zeltia S.A.: Report at 30 June 2006

Madrid, Spain (ots/PRNewswire)

Corporate:
  • Zeltia performs 1-for-50 bonus issue
  • Group revenues amounted to 42.5 million euro.
  • Investment in R&D amounted to 24.4 million euro in the first half of 2006.
  • The net cash position (cash + cash equivalents + current financial assets - short-term borrowings) amounted to 55.3 million euro.
PharmaMar:
- Excellent results of Yondelis in myxoid liposarcomas and ovarian
carcinoma presented at ASCO 2006
NeuroPharma:
- Progress with its first clinical-phase compound
Zelnova:
- Entered the Italian market by acquiring Copyr
Isabel Lozano     Catherine Moukheibir M(a) Luisa de Francia
    Chief Executive   Head of Capital      Chief Financial Officer
    Officer           Market Strategy
                                           ZELTIA, S.A.
    PHARMAMAR, S.A.   ZELTIA, S.A.
                                           José Abascal, 2. Madrid
    C/ Reyes, 1.      José Abascal, 2.
    Colmenar Viejo    Madrid               Telephone +34-91-444-45-00
    Madrid            Telephone
                      +34-91-444-45-00
    Telephone
    +34-91-846-60-00
For a copy of the full results, please refer to www.zeltia.com

Contact:

Isabel Lozano, Chief Executive Officer, PHARMAMAR, S.A., C/Reyes, 1.
Colmenar Viejo, Madrid, Telephone +34-91-846-60-00, Catherine
Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José
Abascal, 2. Madrid, Telephone +34-91-444-45-00, M(a) Luisa de
Francia, Chief Financial Officer, ZELTIA, S.A., José Abascal, 2.
Madrid, Telephone +34-91-444-45-00

Weitere Storys: Zeltia Group
Weitere Storys: Zeltia Group
  • 05.06.2006 – 08:50

    Three New Key Studies at ASCO Highlight Antitumoral Activity of Yondelis(R)

    Atlanta, Georgia (ots/PRNewswire) - - 86% Rate of Tumour Control in myxoid liposarcomas - Correlation Between DNA Repair Gene Expression and Response Rate in Sarcomas - 78% Rate of Tumour Control in Platinum Pretreated Ovarian Cancer Patients PharmaMar highlights the results of three important studies out of 10 presented on Yondelis(R) at the Annual ...

  • 27.04.2006 – 09:24

    Zeltia Increases R&D Investment by 32.2% in the First Quarter 2006

    Madrid (ots/PRNewswire) - - Revenue Amounted to 14.8 Million Euros - Marketing Expenditure Increased 52.1% to 5.1 Million Euros - The Group Invested 11.8 Million Euros in Research and Development, Up 32% Zeltia S.A. (ZEL SM; ZEL MC) today presented its financial results for the first quarter of 2006, which showed a significant increase in Research & Development (R&D) spend, to 11.8 million euros. ...

  • 23.02.2006 – 08:20

    Zeltia: Report at 31 December 2005

    Madrid (ots/PRNewswire) - Group: - Capital increase at Zeltia. The placement of 10.75 million new shares among qualified international investors raised 65 million euro - R&D expenditure up 24% - Net revenues in 2005: 72 million euro - Net cash position at 31 December 2005: 93 million euro net of short-term financial debt and 51 million euro net of total financial debt PharmaMar: - Yondelis(R): - Phase III pivotal trial on ovarian cancer ...